Thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenic purpura


https://doi.org/10.4081/hmr.v3i3.574
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 223
PDF: 840
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Understanding of the pathophysiology of immune thrombocytopenic purpura (ITP) has undergone substantial revision. Harrington and colleagues showed that infusing ITP plasma into healthy recipients caused acute thrombocytopenia. Subsequently, this activity was attributable to the IgG fraction with the effect mitigated by splenectomy or corticosteroids. Formal studies of platelet kinetics affirmed that platelet survival is shortened in ITP. It was inferred from these studies, the abundance of megakaryocytes in the bone marrow and the appearance of young megathrombocytes in the periphery, that increased platelet production compensates for platelet destruction, analogous to reticulocytosis in autoimmune hemolytic anemia. Corticosteroids, danazol, IV immune globulin or IV anti-D worked by reducing clearance of antibody-coated platelets by tissue macrophages.

Supporting Agencies


Cuker, A., Chiang, E., & Cines, D. (2009). Thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenic purpura. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.574
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC